Myelodysplastic Syndromes (MDS); diagnosis, classification, treatment and monitoring
نویسندگان
1 Department of Hematology and Blood Banking, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
2 Department of Hematology and Blood Banking, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
3 Department of Hematology and Blood Banking, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
4 Department of Microbiology and Microbial Biotechnology, Faculty of Life Sciences and Biotechnology, Shahid Beheshti University, Tehran, Iran
5 Department of hematology and oncology, school of allied medical sciences, Shahid Beheshti University of medical sciences, Tehran, Iran
doi
10.58209/ijbc.14.3.71چکیده
Due to the neoplastic nature of myelodysplastic syndromes (MDS), they have been renamed as myelodysplastic neoplasms in the World Health Organization (WHO) 2022 classification. These syndromes are heterogeneous groups of myeloid disorders characterized by dysplasia of bone marrow cells, ineffective hematopoiesis, increased apoptosis, peripheral blood cytopenia, and risk of progression ...
